Long-Term, Open Label Atomoxetine Study

Completed · Phase 3

Conditions studied: Attention Deficit Hyperactivity Disorder

In brief

To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for about 5 years (long-term). Study participants can be atomoxetine naive, atomoxetine experienced whose therapy has been interrupted or, atomoxetine experienced on a known stable dose.

Key facts

Study ID
NCT00190684
Run by
Eli Lilly and Company
People needed
1553
Starts
2000-08-01
Expected to finish
2009-10-01
Last updated by the study team
2011-01-17

Who can join

Age: 6 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.